The Sector plays a big role in the investment decisions. One should never bet against the market narrative in the short term. But there are always winners, even in a sector where everyone struggles. One can take the case of Target and Walmart in Retail and Pfizer and Teva in Pharma.
Target – Road to Nowhere
Minneapolis-based Target Corp. operates nearly 2,000 retail stores and an e-commerce site. It’s working hard now to win over customers in a busy holiday season with generative AI shopping tools but as you can see in the chart below, the stock has gone nowhere in 2024. It’s bouncing up and down with the earnings report. The company lacks clear positioning and is losing to competitors like Walmart and Costco.
Target is a profitable company with an attractive dividend yield and solid fundamentals. It’s a good value play but the company lacks direction. No wonder the stock has fallen out of favor with the market
Walmart is winning the retail game
Walmart stock is up 80% for the year, and see the chart below – the stock has rallied on every earnings report this year [see points 1,2,3 and 4 on the chart]. It means perfect execution. The company has done well in an inflationary environment by serving its budget-conscious consumers. Walmart is famous for low prices and large stores but what changed in 2024 is running Walmart.com online store as Amazon. The shopping experience has improved a lot and the company is making the most of it to drive growth. 
If that’s not all – Sam’s Club, Walmart’s wholesale club business also experienced significant growth. When one company executes well, then it leads to a big divergence in the stock performance.
Case study of Pfizer and Teva
Why should one avoid Pfizer?
Pfizer stock is up 4.5% today. The company issued an upbeat full-year outlook for 2025. The company projects annual sales between $61 billion and $64 billion, with earnings per share estimates at $2.80 to $3 — both metrics in line with Wall Street projections. But does this matter? Will it change the sentiment?
The price action is horrible.
When in doubt, Stay out. It’s extremely hard for any stock to perform when the economic environment is hostile to the business. There is a general mood against big pharma in terms of how expensive they are and how ineffective they are against chronic illnesses.
What about Teva’s big move?
Follow the History. TEVA, unlike Pfizer, is having a great year. There was a Gap-up move post earnings report in May 2024, and the stock rallied 30% to $19 and then peaked at that level. The stock sold off in Nov after earnings, but then the stock found support at 200 dma – a clear sign that traders/investors like the stock.
Teva stock is up on the news today that its drug is working on patients with ulcerative colitis and Crohn’s disease ( inflammatory bowel disease). The stock has broken out above $19 and will likely go much higher. If I have to pick a stock in Pharma – Teva would be the one.
The Winners
Chart Source: Finviz.com
Please do your own due diligence before trading. Nothing here or in the newsletters constitutes financial advice. These are just my views based on my experience.
Leave a Reply
You must be logged in to post a comment.